BTX 1204: atopic dermatitis – next steps Botanix is pursuing a rapid clinical development strategy to accelerate product commercialisation and timing to first revenues Milestones Phase 1b atopic dermatitis patient data Pre- IND meeting for FDA regulated Phase 2 trial 2Q 2019 ,
Plenty of time before any meaningful results back here at BOT..
BTX 1204: atopic dermatitis – next steps Botanix is pursuing a...
-
- There are more pages in this discussion • 74 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
35.0¢ |
Change
-0.005(1.41%) |
Mkt cap ! $707.4M | |||
| Open | High | Low | Value | Volume |
| 36.0¢ | 36.0¢ | 35.0¢ | $335.6K | 951.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 199121 | 35.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 35.5¢ | 188812 | 12 |
View Market Depth
| Last trade - 11.58am 27/11/2024 (20 minute delay) ? |
| BOT (ASX) Chart |
